|
Age, sex, and disease duration since diagnosis |
||||||
| Rheumatoid arthritisa |
Psoriatic arthritis |
Ankylosing spondylitis |
||||
| Placebo n = 450 |
IFX n = 1061 |
Placebo n = 100 |
IFX n = 100 |
Placebo n = 78 |
IFX n = 201 |
|
|
|
||||||
| Sex, % women |
82% |
78% |
49% |
29% |
13% |
22% |
| Age (years)b |
52.2 (12.3) |
51.8 (12.4) |
46.5 (11.3) |
47.1 (12.8) |
40.3 (9.4) |
39.6 (10.6) |
| Range |
(19, 85) |
(18, 89) |
(24, 71) |
(18, 80) |
(20, 74) |
(18, 71) |
| Disease duration (years)b |
9.9 (8.8) |
10.3 (9.1) |
7.5 (7.8) |
8.4 (7.2) |
11.9 (8.0) |
10.1 (8.7) |
| Range |
(0.3, 41.5) |
(0.3, 55.5) |
(0.3, 38.5) |
(0.4, 29.2) |
(0.3, 31.6) |
(0.3, 41.1) |
|
aAll patients were receiving concomitant methotrexate; bValues are mean (standard deviation) unless otherwise indicated. IFX, infliximab. | ||||||
Han et al. Arthritis Research & Therapy 2007 9:R103 doi:10.1186/ar2306 |
||||||